help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reubi, J. C.
Right arrow Articles by Mengod, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reubi, J. C.
Right arrow Articles by Mengod, G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Brain Cancer

Journal of Clinical Endocrinology & Metabolism, Vol 76, 642-647, Copyright © 1993 by Endocrine Society

ARTICLES

Somatostatin (SRIH) messenger ribonucleic acid expression in human neuroendocrine and brain tumors using in situ hybridization histochemistry: comparison with SRIH receptor content

JC Reubi, B Waser, SW Lamberts and G Mengod
Sandoz Research Institute Berne Ltd., University of Berne, Switzerland.

Somatostatin (SRIH) receptors are expressed in a large number of neuroendocrine and brain tumors. To evaluate the potential of these tumors locally to produce the SRIH required to bind to SRIH receptors, we have investigated in 158 human tumors whether they express mRNA for SRIH, using in situ hybridization. Among 78 neuroendocrine tumors tested, 13 of 13 medullary thyroid carcinomas, 19 of 34 pheochromocytomas, 3 of 11 paragangliomas, 0 of 4 small cell lung cancers, 4 of 9 adrenal neuroblastomas, and 4 of 7 gastroenteropancreatic tumors contained SRIH mRNA. Among 47 central nervous system and meningeal tumors tested, including 23 meningiomas, 9 astrocytomas, 4 oligodendrogliomas, and 11 glioblastomas, none expressed SRIH mRNA. Unexpectedly, 16 of 33 ovarian tumors, including adenocarcinomas and borderline tumors, expressed SRIH mRNA. These results suggest that a large proportion of neuroendocrine tumors have the ability to express SRIH mRNA, whereas central nervous system tumors do not. The presence of SRIH mRNA in half of the tested ovarian tumors suggests that those tumors may be hormone producing and have neuroendocrine features. The presence of SRIH receptors in most of the neuroendocrine tumors together with the ability of many of those tumors to synthesize SRIH point toward an autocrine regulatory feedback mechanism of SRIH in these tissues.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
Q. Liu, J.-C. Reubi, Y. Wang, B. J. Knoll, and A. Schonbrunn
In Vivo Phosphorylation of the Somatostatin 2A Receptor in Human Tumors
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6073 - 6079.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. D. Zapata, R. M. Ropero, A. M. Valencia, L. Buscail, J. I. Lopez, R. M. Martin-Orozco, J. C. Prieto, J. Angulo, C. Susini, P. Lopez-Ruiz, et al.
Autocrine Regulation of Human Prostate Carcinoma Cell Proliferation by Somatostatin through the Modulation of the SH2 Domain Containing Protein Tyrosine Phosphatase (SHP)-1
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 915 - 926.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. C. Reubi, B. Waser, Q. Liu, J. A. Laissue, and A. Schonbrunn
Subcellular Distribution of Somatostatin sst2A Receptors in Human Tumors of the Nervous and Neuroendocrine Systems: Membranous Versus Intracellular Location
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3882 - 3891.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
H. Kiaris, A. V. Schally, A. Nagy, B. Sun, K. Szepeshazi, and G. Halmos
Regression of U-87 MG Human Glioblastomas in Nude Mice after Treatment with a Cytotoxic Somatostatin Analog AN-238
Clin. Cancer Res., February 1, 2000; 6(2): 709 - 717.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
N. Kimura, M. Pilichowska, F. Date, I. Kimura, and M. Schindler
Immunohistochemical Expression of Somatostatin Type 2A Receptor in Neuroendocrine Tumors
Clin. Cancer Res., November 1, 1999; 5(11): 3483 - 3487.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. C. Reubi, A. Kappeler, B. Waser, J. Laissue, R. W. Hipkin, and A. Schonbrunn
Immunohistochemical Localization of Somatostatin Receptors sst2A in Human Tumors
Am. J. Pathol., July 1, 1998; 153(1): 233 - 245.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S Angeletti, V D Corleto, O Schillaci, M Marignani, B Annibale, A Moretti, G Silecchia, F Scopinaro, N Basso, C Bordi, et al.
Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours
Gut, June 1, 1998; 42(6): 792 - 794.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. J. Hofland, W. W. de Herder, H. A. Visser-Wisselaar, C. van Uffelen, M. Waaijers, J. Zuyderwijk, P. Uitterlinden, M. J. M. Kros, P. M. van Koetsveld, and S. W. J. Lamberts
Dissociation between the Effects of Somatostatin (SS) and Octapeptide SS-Analogs on Hormone Release in a Small Subgroup of Pituitary- and Islet Cell Tumors
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3011 - 3018.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society